Rheumatoid arthritis
- PMID: 11567728
- DOI: 10.1016/S0140-6736(01)06075-5
Rheumatoid arthritis
Abstract
Rheumatoid arthritis is a systemic inflammatory disorder that mainly affects the diarthrodial joint. It is the most common form of inflammatory arthritis, and has a substantial societal effect in terms of cost, disability, and lost productivity. Although the pathogenesis of rheumatoid arthritis remains incompletely understood, much insight into the cellular and molecular mechanisms involved has been gained in the past decade. On the basis of these insights, new therapies have been developed, and clinical trials have shown the efficacy of aggressive treatment of patients with active disease. In this review, we discuss improvements in our understanding of the pathophysiology of inflammatory synovitis in rheumatoid arthritis, and improvements in therapy for patients with the disorder. The past decade has seen substantial advances in these areas. Future studies will be directed at improving methods for early diagnosis and identification of patients with progressive disease, and at improving methods to identify candidates for subclasses of disease-modifying antirheumatic drugs (DMARDs). Long-term safety and efficacy data for the new DMARD agents and combination regimens will also further delineate efficacy and toxicity and thus the appropriate clinical context for use of these therapeutic approaches. The continuing elucidation of pathophysiological pathways relevant in rheumatoid arthritis, coupled with continuing advances in biotechnology and rational drug design, offer substantial hope for the continued development of increasingly potent and specific pharmacotherapy for treatment of rheumatoid arthritis.
Comment in
-
Biological response modifiers in rheumatoid arthritis.Lancet. 2002 Jan 26;359(9303):352. doi: 10.1016/s0140-6736(02)07508-6. Lancet. 2002. PMID: 11830225 No abstract available.
Similar articles
-
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.Arthritis Rheum. 2004 Jan;50(1):55-62. doi: 10.1002/art.11436. Arthritis Rheum. 2004. PMID: 14730599 Clinical Trial.
-
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).J Rheumatol. 2003 Dec;30(12):2563-71. J Rheumatol. 2003. PMID: 14719195 Clinical Trial.
-
Pharmacogenetics in rheumatoid arthritis.Methods Mol Biol. 2014;1175:625-60. doi: 10.1007/978-1-4939-0956-8_16. Methods Mol Biol. 2014. PMID: 25150878
-
Rheumatoid arthritis: an overview of new and emerging therapies.J Clin Pharmacol. 2005 Jul;45(7):751-62. doi: 10.1177/0091270005277938. J Clin Pharmacol. 2005. PMID: 15951465 Review.
-
Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.Curr Opin Rheumatol. 2010 May;22(3):316-20. doi: 10.1097/BOR.0b013e3283383f87. Curr Opin Rheumatol. 2010. PMID: 20190639 Review.
Cited by
-
An update on stem cell transplantation in autoimmune rheumatologic disorders.Curr Allergy Asthma Rep. 2012 Dec;12(6):530-40. doi: 10.1007/s11882-012-0298-8. Curr Allergy Asthma Rep. 2012. PMID: 22956390 Review.
-
Neurologic manifestations of systemic immunopathological diseases.Curr Treat Options Neurol. 2012 Jun;14(3):276-92. doi: 10.1007/s11940-012-0171-z. Curr Treat Options Neurol. 2012. PMID: 22399412
-
Suboptimal management of rheumatoid arthritis in the Middle East and Africa: could the EULAR recommendations be the start of a solution?Clin Rheumatol. 2013 Feb;32(2):151-9. doi: 10.1007/s10067-012-2153-7. Epub 2012 Dec 30. Clin Rheumatol. 2013. PMID: 23274756
-
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.Int J Rheum Dis. 2016 Nov;19(11):1157-1168. doi: 10.1111/1756-185X.12711. Epub 2015 Jul 14. Int J Rheum Dis. 2016. PMID: 26176644 Free PMC article. Clinical Trial.
-
Linc02381 Exacerbates Rheumatoid Arthritis Through Adsorbing miR-590-5p and Activating the Mitogen-Activated Protein Kinase Signaling Pathway in Rheumatoid arthritis-fibroblast-like synoviocytes.Cell Transplant. 2020 Jan-Dec;29:963689720938023. doi: 10.1177/0963689720938023. Cell Transplant. 2020. PMID: 32608996 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous